A poster by Anthony Renodon, Business Development Officer, Treefrog Therapeutics
2D cell culture has been widely used to manufacture the first generation of cell therapies.
However, due to the drawbacks of scale-out processes (footprint, workforce use, variability and subsequent QC expenses), the industry is shifting towards the gold-standard for bioproduction scale-up, i.e. bioreactors, with the goal of addressing mass-markets with standardized and affordable products.
Here using new C-Stemâ technology based on a high-speed cell encapsulation microfluidics, we report the production of two single batches of 15 billion hiPSCs in 10L bioreactors with an unprecedented 276-fold amplification within a week.
Data demonstrates high-reproducibility and maintenance of best-in-class cell viability and pluripotency.
Also documenting the scale-independent amplification profile obtained with C-Stemâ in 30mL, 500mL, 1.5L and 10L bioreactors, we argue that the C-Stemâ technology is amenable to produce commercial-size batches of stem cells in larger bioreactors.
